First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
Search
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer
Effective management practices for parasite control in cattle
Effective management practices for parasite control in cattle
Boehringer Ingelheim (Canada) Ltd. partners with LMC Healthcare on national diabetes prevention program
Boehringer Ingelheim (Canada) Ltd. partners with LMC Healthcare on national diabetes prevention program
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
University Health Network and Boehringer Ingelheim Canada partner to impact patients lives and help a healthcare system under strain
University Health Network and Boehringer Ingelheim Canada partner to impact patients lives and help a healthcare system under strain
Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV
Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV
Innovative health projects impact thousands of Indigenous Peoples in Canada
Innovative health projects impact thousands of Indigenous Peoples in Canada
Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients
Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients
Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities
Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches
New partnership in Alberta supports healthcare solutions for interstitial lung diseases
New partnership in Alberta supports healthcare solutions for interstitial lung diseases
Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project
Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project
GPP
GPP
Strategies for overcoming resistance in parasites
Strategies for overcoming resistance in parasites
Prevention is the first line of defense
Prevention is the first line of defense
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
Ingelvac CircoFLEX®: The most successful animal health vaccine of all time is also a very versatile product
Ingelvac CircoFLEX®: The most successful animal health vaccine of all time is also a very versatile product
New initiative helps over 16,000 healthcare providers gain critical knowledge about palliative care during COVID-19
New initiative helps over 16,000 healthcare providers gain critical knowledge about palliative care during COVID-19
More Health: For People & Animals
More Health: For People & Animals
Boehringer Ingelheim Canada and community-based clinics join to revolutionize cardiovascular care in Ontario
Boehringer Ingelheim Canada and community-based clinics join to revolutionize cardiovascular care in Ontario
Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure
Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure
Western Canada
Boehringer Ingelheim Canada works hand in hand with prominent institutions in Western Canada. Find out more about our partnerships and their initiatives.